DANILO CORALES: Open Payments
NPI 1013951771 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,260 in 120 payments from 33 companies in 2025. Trend: 2023 $2,070 · 2024 $2,649 · 2025 $2,260
Food & beverage: $2,260
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $380 |
| Amgen Inc. | 17 | $281 |
| Lilly USA, LLC | 12 | $220 |
| PFIZER INC. | 14 | $204 |
| GlaxoSmithKline, LLC. | 6 | $101 |
| Vanda Pharmaceuticals Inc. | 4 | $95 |
| ABBVIE INC. | 4 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| Novartis Pharmaceuticals Corporation | 3 | $63 |
| SANOFI-AVENTIS U.S. LLC | 3 | $62 |
Products named: OTEZLA, Ozempic, JARDIANCE, ELIQUIS, TRELEGY ELLIPTA, Wegovy, MOUNJARO, Rybelsus.
Industry payments across KY — which companies pay providers there.
